Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma?

被引：0
|
作者：
Kim, Do Young [1 ]
机构：
[1] Yonsei Univ, Coll Med, Dept Internal Med, 50-1 Yonsei Ro, Seoul 03722, South Korea
来源：
CLINICAL AND MOLECULAR HEPATOLOGY | 2017年 / 23卷 / 02期
关键词：
Hepatocellular carcinoma; Sorafenib; Hepatic arterial infusion chemotherapy; Metronomic chemotherapy; HEPATIC ARTERIAL INFUSION; LIVER-CANCER; CISPLATIN; 5-FLUOROURACIL;
D O I：
10.3350/cmh.2017.0107
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：123 / 124
页数：2
相关论文
共 50 条
  • [1] The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma
    Jeong, Soung Won
    Jang, Jae Young
    Lee, Ji Eun
    Lee, Sae Hwan
    Kim, Sang Gyune
    Cha, Sang-Woo
    Kim, Young Seok
    Cho, Young Deok
    Kim, Hong Soo
    Kim, Boo Sung
    Kim, Kyoung Ha
    Kim, Yong Jae
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 (02) : 164 - 171
  • [2] Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age
    Miyahara, Koji
    Nouso, Kazuhiro
    Yamamoto, Kazuhide
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (15) : 4151 - 4159
  • [3] Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age
    Koji Miyahara
    Kazuhiro Nouso
    Kazuhide Yamamoto
    World Journal of Gastroenterology, 2014, (15) : 4151 - 4159
  • [4] Metronomic Chemotherapy: Possible Clinical Application in Advanced Hepatocellular Carcinoma
    Torimura, Takuji
    Iwamoto, Hideki
    Nakamura, Toru
    Koga, Hironori
    Ueno, Takato
    Kerbel, Robert S.
    Sata, Michio
    TRANSLATIONAL ONCOLOGY, 2013, 6 (05): : 511 - 519
  • [5] Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments
    Suzuki, Hiroyuki
    Iwamoto, Hideki
    Nakano, Masahito
    Nakamura, Toru
    Masuda, Atsutaka
    Sakaue, Takahiko
    Tanaka, Toshimitsu
    Nakano, Dan
    Kuromatsu, Ryoko
    Niizeki, Takashi
    Okamura, Shusuke
    Shimose, Shigeo
    Shirono, Tomotake
    Noda, Yu
    Kamachi, Naoki
    Yano, Hirohisa
    Kawaguchi, Atsushi
    Koga, Hironori
    Torimura, Takuji
    TRANSLATIONAL ONCOLOGY, 2021, 14 (11):
  • [6] Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
    Hsu, Chih-Hung
    Shen, Ying-Chun
    Lin, Zhong-Zhe
    Chen, Pei-Jer
    Shao, Yu-Yun
    Ding, Yea-Hui
    Hsu, Chiun
    Cheng, Ann-Lii
    JOURNAL OF HEPATOLOGY, 2010, 53 (01) : 126 - 131
  • [7] Development of a Resistance-like Phenotype to Sorafenib by Human Hepatocellular Carcinoma Cells Is Reversible and Can Be Delayed by Metronomic UFT Chemotherapy
    Tang, Terence C.
    Man, Shan
    Xu, Ping
    Francia, Giulio
    Hashimoto, Kae
    Emmenegger, Urban
    Kerbel, Robert S.
    NEOPLASIA, 2010, 12 (11): : 928 - 940
  • [8] Sorafenib in advanced hepatocellular carcinoma
    Sauerbruch, T.
    Gonzalez-Carmona, A. M.
    Nitschmann, S.
    INTERNIST, 2009, 50 (11): : 1290 - 1292
  • [9] Sorafenib in advanced hepatocellular carcinoma
    Llovet, Josep M.
    Ricci, Sergio
    Mazzaferro, Vincenzo
    Hilgard, Philip
    Gane, Edward
    Blanc, Jean-Frederic
    Cosme de Oliveira, Andre
    Santoro, Armando
    Raoul, Jean-Luc
    Forner, Alejandro
    Schwartz, Myron
    Porta, Camillo
    Zeuzem, Stefan
    Bolondi, Luigi
    Greten, Tim F.
    Galle, Peter R.
    Seitz, Jean-Francois
    Borbath, Ivan
    Haussinger, Dieter
    Giannaris, Tom
    Shan, Minghua
    Moscovici, Marius
    Voliotis, Dimitris
    Bruix, Jordi
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04): : 378 - 390
  • [10] Sorafenib for Advanced Hepatocellular Carcinoma
    Shingina, Alexandra
    Hashim, ALMoutaz
    Haque, Mazhar
    Suen, Michael W.
    Yoshida, Eric M.
    Gill, Sharlene
    Weiss, Alan
    GASTROENTEROLOGY, 2012, 142 (05) : S42 - S42
12345